{Reference Type}: Journal Article
{Title}: Metformin treatment results in distinctive skeletal muscle mitochondrial remodeling in rats with different intrinsic aerobic capacities.
{Author}: Bubak MP;Davidyan A;O'Reilly CL;Mondal SA;Keast J;Doidge SM;Borowik AK;Taylor ME;Volovičeva E;Kinter MT;Britton SL;Koch LG;Stout MB;Lewis TL;Miller BF;
{Journal}: Aging Cell
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 24
{Factor}: 11.005
{DOI}: 10.1111/acel.14235
{Abstract}: The rationale for the use of metformin as a treatment to slow aging was largely based on data collected from metabolically unhealthy individuals. For healthspan extension metformin will also be used in periods of good health. To understand the potential context specificity of metformin treatment on skeletal muscle, we used a rat model (high-capacity runner/low-capacity runner [HCR/LCR]) with a divide in intrinsic aerobic capacity. Outcomes of metformin treatment differed based on baseline intrinsic mitochondrial function, oxidative capacity of the muscle (gastroc vs soleus), and the mitochondrial population (intermyofibrillar vs. subsarcolemmal). Metformin caused lower ADP-stimulated respiration in LCRs, with less of a change in HCRs. However, a washout of metformin resulted in an unexpected doubling of respiratory capacity in HCRs. These improvements in respiratory capacity were accompanied by mitochondrial remodeling that included increases in protein synthesis and changes in morphology. Our findings raise questions about whether the positive findings of metformin treatment are broadly applicable.